Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Ascelia Pharma - Final outcome of rights issue

By HC Andersen Capital
Ascelia Pharma

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to CEO Magnus Corfitzen on 10 September 2024 at 2.00PM.

The company has secured approximately SEK 105 million in gross proceeds before issue costs. The issue was completed without guarantors.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – Orviglance in Phase 3 and Oncoral in clinical development, but for the moment on hold. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup, 6 September 09.23AM.

Recent videos

H&M Q1´26: Bättre marginaler men svag tillväxt
2026-03-31 12:13 H&M
Thule Group, Audiocast, Pre-silent 26
2026-03-30 16:00 Thule Group
Puuilo Q4’25: Still the star in the sector
2026-03-30 13:35 Puuilo
Jack Paulsson: Hellre börsen än Paradise Hotel
2026-03-26 09:09
Kreate - Varsinainen Yhtiökokous 2026
2026-03-26 09:00 Kreate Group
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.